Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06819670 · ClinicalTrials.gov registry record · Phase 2
A Study to Prevent Infantile Spasms Relapse
A Phase 2 study of Infantile Spasms and Infantile Epileptic Spasms Syndrome, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06819670 is a Phase 2 study of Infantile Spasms and Infantile Epileptic Spasms Syndrome that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06819670, a Phase 2 study of Infantile Spasms and Infantile Epileptic Spasms Syndrome, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
After initially successful treatment, many children with infantile spasms unfortunately have a relapse, and relapse is linked to poor long-term outcomes such as autism and other forms of epilepsy. The aim of this study is to determine if treatment with low-dose prednisolone is safe, well tolerated, and effective in reducing the risk of relapse.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Prednisolone
- DRUG Famotidine
Study Locations (1)
California
- UCLA - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-05-05 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06819670
The ClinicalTrials.gov registry entry for NCT06819670 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Infantile Spasms appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06819670 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06819670 about?
NCT06819670 is a clinical study titled "A Study to Prevent Infantile Spasms Relapse". After initially successful treatment, many children with infantile spasms unfortunately have a relapse, and relapse is linked to poor long-term outcomes such as autism and other forms of epilepsy. The aim of this study is to determine if treatment with low-dose prednisolone is safe, well tolerated, ...
What is the current status of trial NCT06819670?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-05-05. Estimated completion is 2028-06-30.
What conditions does trial NCT06819670 study?
This clinical trial studies the following conditions: Infantile Spasms, Infantile Epileptic Spasms Syndrome, West Syndrome.
What interventions are being tested in trial NCT06819670?
The interventions under investigation include: Placebo (DRUG), Prednisolone (DRUG), Famotidine (DRUG).
Who is sponsoring clinical trial NCT06819670?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06819670 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infantile Spasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.